Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients

Phase 2

Completed

• Conditions: COVID-19
• Interventions: Other: Placebo; Drug: Calcitriol

• Registration Number: NCT05765617
• Lead Sponsor: Universitas Sebelas Maret

Brief Summary

This research is a study that compares the administration of calcitriol with the outcomes of COVID-19 patients

Detailed Description

This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into two groups. The control group received standard therapy, while the treatment group received calcitriol 2x400 iu per day.

Study Timeline

• Study Start: 2021-07-01
• Primary Completion: 2021-09-30
• Study Completion: 2021-09-30
• Status Verified: 2023-03
• Study First Submitted: 2023-03-09
• Study First Submitted QC: 2023-03-09
• Last Update Submitted: 2023-03-09
• Study First Posted: 2023-03-13
• Last Update Posted: 2023-03-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• COVID-19 patients, hospitalized patients, and patients aged 18-60 years

Exclusion Criteria

• pregnancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control	Placebo	Placebo 2x1 per day
Calcitriol	Calcitriol	the treatment group received calcitriol 2x400 iu per day for 5 day

Primary Outcome Measures

Name	Time	Method
HsCRP	Hs CRP (high sensitive c reactive protein) examination was carried out on the first day of hospitalization and the 5th day of hospitalization	High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation

Trial Locations

Locations (1)

Universitas Sebelas Maret Hospital; 🇮🇩 Sukoharjo, Central Java, Indonesia